Spots Global Cancer Trial Database for Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Official Title: A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Oral Lenalidomide & Dexamethasone in Adult Patients With Multiple Myeloma
Study ID: NCT00532675
Conditions
Study Description
Brief Summary: This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCSF Medical Center, San Francisco, California, United States
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst., Atlanta, Georgia, United States
St. Vincent's Comprehensive Cancer Center, New York, New York, United States
Novartis Investigative Site, South Brisbane, Queensland, Australia
Novartis Investigative Site, Prahran, Victoria, Australia
Novartis Investigative Site, Lille, , France
Novartis Investigative Site, Montpellier cedex 5, , France
Novartis Investigative Site, Nantes, , France
Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
